ESTRO 2025 - Abstract Book

S1571

Clinical – Mixed sites & palliation

ESTRO 2025

Results:

27 patients treated with STAR were included with a median follow-up of 36 months [IQR 21-50]. Median age was 67 [61-74], 85% were men (n=23) and 52% suffered from nonischaemic cardiomyopathy (n=14). 20 patients were treated with RGSS (median PTV 26cc [19-39]) and 7 with VMAT (median PTV 210cc [151-267]). During follow-up, 7 grade ≥3 STAR -related AEs were observed (Table 1). There was a statistically significant difference in prescribed mean dose to the whole heart, comparing the two patients (both VMAT) with in total three grade ≥3 pericardial effusion AEs (10.7 Gy [range 10.3-11.2]) to patients without pericardial effusion AEs (6.1 Gy [range 2.8-13.4] (P=0.023). In the other grade ≥3 AE -related OARs, no significant difference in prescribed dose comparing patients with and without AEs was observed. The patient experiencing cardiac chest pain had previously undergone coronary-artery bypass grafting and the relevant bypasses could not be delineated. Conclusion: In this study evaluating the mid-term safety of STAR for therapy-refractory VT, seven STAR-related severe adverse events were observed. Patients experiencing severe pericardial effusion received a statistically significant higher radiotherapy dose to the whole heart compared to those without severe pericardial effusion.

Keywords: Stereotactic Arrhythmia Radiotherapy, STAR

3990

Proffered Paper Esophagus-sparing radiotherapy for metastatic spinal cord compression (ESO-SPARE). A phase III randomized clinical trial. Anna Mann Nielsen 1 , Michael R.T. Lauersen 1 , Katrine S Storm 1 , Vanja R Gram 1 , Laura A. Rechner 1 , Wiviann ottosson 1 , Morten H. Suppli 2 , Patrik Sibolt 1 , Claus P. Behrens 1,3 , Ivan R. Vogelius 2,4 , Gitte Persson 1,4 1 Department of Oncology, Copenhagen University Hospital – Herlev and Gentofte,, Copenhagen, Denmark. 2 Department of Oncology, Copenhagen University Hospital – Rigshospitalet, Copenhagen, Denmark. 3 Department of Health Technology, Technical University of Denmark, Lyngby, Denmark. 4 Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark

Purpose/Objective: Palliative radiotherapy (RT) is used to relieve symptoms of metastatic spinal cord compression (MSCC), but treatment-related dysphagia may be a concern in patients irradiated in the cervical and thoracic spine. 1 We